CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $261.23M, lower than 95% of all stocks globally
- PositionReturn on equity is 27.1%, higher than 95% of its Biotechnology peers (median -21.7%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
261.23MUSDvs all stocks (USD)
Trailing P/E
15.62xvs Biotechnology peers
Revenue (TTM)
130.42MUSDvs all stocks (USD)
Profit Margin
14.29%vs Biotechnology peers
Beta
2.08xvs all stocks
52-Week Change
-66.12%vs all stocks
Market Capitalization
261.23MUSDvs all stocks (USD)
Enterprise Value
197.96MUSDvs all stocks (USD)
Trailing P/E
15.62xvs Biotechnology peers
Forward P/E
10.25xvs Biotechnology peers
PEG Ratio
1.09xvs Biotechnology peers
Price to Sales (TTM)
2.00xvs Biotechnology peers
Price to Book (MRQ)
3.17xvs Biotechnology peers
Enterprise to Revenue
1.52xvs Biotechnology peers
Enterprise to EBITDA
16.52xvs Biotechnology peers
Gross Margin
63.47%vs Biotechnology peers
Profit Margin
14.29%vs Biotechnology peers
Operating Margin
5.01%vs Biotechnology peers
Return on Assets (TTM)
7.09%vs Biotechnology peers
Return on Equity (TTM)
27.07%vs Biotechnology peers
Revenue (TTM)
130.42MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.64USDUpdated Jul 19, 2026Quarterly Revenue Growth
3.30%vs Biotechnology peers
Gross Profit (TTM)
83.83MUSDvs all stocks (USD)
EBITDA (TTM)
13.76MUSDvs all stocks (USD)
Net Income (TTM)
18.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
24.80%vs Biotechnology peers
Operating Cash Flow (TTM)
4.43MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.20MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
129.42MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
46.23MUSDFY2025 · Dec 31, 2025Gross Profit
83.19MUSDFY2025 · Dec 31, 2025Operating Income
14.30MUSDvs all stocks (USD)
Pre-tax Income
18.19MUSDFY2025 · Dec 31, 2025Income Tax Expense
810.00KUSDFY2025 · Dec 31, 2025Net Income
17.38MUSDFY2025 · Dec 31, 2025EBIT
14.30MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
13.76MUSDFY2025 · Dec 31, 2025Research & Development
6.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
62.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.13MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.2200USDFY2025 · Dec 31, 2025EPS (Diluted)
0.2000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
79.18MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
79.18MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
17.38MUSDFY2025 · Dec 31, 2025Operating Cash Flow
11.76MUSDFY2025 · Dec 31, 2025Free Cash Flow
11.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
64.79MUSDFY2025 · Dec 31, 2025Interest Paid
1.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
17.38MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.45MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.95MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-756.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.27MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.71MUSDFY2025 · Dec 31, 2025Capital Expenditures
-292.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-292.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-12.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-251.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-67.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-330.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
79.46MSharesUpdated Jul 19, 2026Float Shares
59.59MSharesUpdated Jul 19, 2026Shares Short
4.39MSharesUpdated Jul 19, 2026Short Ratio
6.07daysvs all stocks
Short % of Shares Outstanding
8.47%vs all stocks
% Held by Insiders
29.26%vs all stocks
% Held by Institutions
47.17%vs all stocks
Total Cash (MRQ)
66.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8320USDUpdated Jul 19, 2026Total Debt (MRQ)
2.58MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0313xvs Biotechnology peers
Current Ratio (MRQ)
4.61xvs Biotechnology peers
Book Value per Share (MRQ)
1.03USDUpdated Jul 19, 2026Total Assets
106.41MUSDvs all stocks (USD)
Total Current Assets
96.81MUSDFY2025 · Dec 31, 2025Total Liabilities
29.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
9.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
9.95MUSDFY2025 · Dec 31, 2025Total Current Liabilities
19.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
64.64MUSDFY2025 · Dec 31, 2025Accounts Receivable
9.74MUSDFY2025 · Dec 31, 2025Inventory
20.42MUSDFY2025 · Dec 31, 2025Accounts Payable
10.80MUSDFY2025 · Dec 31, 2025Short-term Debt
1.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
399.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.81MUSDFY2025 · Dec 31, 2025Common Stock (Book)
79.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-164.53MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
76.53MUSDvs all stocks (USD)
52-Week Low
3.18USDUpdated Jul 19, 202652-Week High
11.29USDUpdated Jul 19, 202652-Week Change
-66.12%vs all stocks
Beta
2.08xvs all stocks
50-Day MA
3.58USDUpdated Jul 19, 2026200-Day MA
5.38USDUpdated Jul 19, 2026Avg 10-Day Volume
776.60KSharesUpdated Jul 19, 2026Avg 30-Day Volume
718.63KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.2100USDUpdated Jul 19, 2026Other Income / Expense
1.77MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 27.1%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.27Industry median: -0.22Industry P95: 0.23Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 18,637,000Operating Cash Flow (USD, TTM): 4,427,000
Financial Health
Altman Z-Score 5.61: safe zoneNotable
Altman Z-Score: 5.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $261.23M, lower than 95% of all stocks globallySignificant
Market cap (USD): 261,233,392Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
D'Alba Global Co., Ltd.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
Keeper Technical Laboratory
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
AJ Bell plc
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover